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ABSTRACT
Introduction The Cognitive Health in Ageing Register: 
Investigational, Observational and Trial Studies in Dementia 
Research (CHARIOT): Prospective Readiness cOhort (PRO) 
SubStudy (CPSS), sponsored by Janssen Pharmaceutical 
Research & Development LLC, is an Alzheimer’s disease 
(AD) biomarker enriched observational study that began 3 
July 2015 CPSS aims to identify and validate determinants 
of AD, alongside cognitive, functional and biological 
changes in older adults with or without detectable 
evidence of AD pathology at baseline.
Methods and analysis CPSS is a dual- site longitudinal 
cohort (3.5 years) assessed quarterly. Cognitively normal 
participants (60–85 years) were recruited across Greater 
London and Edinburgh. Participants are classified as 
high, medium (amnestic or non- amnestic) or low risk for 
developing mild cognitive impairment–Alzheimer’s disease 
based on their Repeatable Battery for the Assessment 
of Neuropsychological Status performance at screening. 
Additional AD- related assessments include: a novel 
cognitive composite, the Global Preclinical Alzheimer’s 
Cognitive Composite, brain MRI and positron emission 
tomography and cerebrospinal fluid analysis. Lifestyle, 
other cognitive and functional data, as well as biosamples 
(blood, urine, and saliva) are collected. Primarily, study 
analyses will evaluate longitudinal change in cognitive 
and functional outcomes. Annual interim analyses for 
descriptive data occur throughout the course of the study, 
although inferential statistics are conducted as required.
Ethics and dissemination CPSS received ethical 
approvals from the London—Central Research Ethics 
Committee (15/LO/0711) and the Administration of 
Radioactive Substances Advisory Committee (RPC 
630/3764/33110) The study is at the forefront of global 
AD prevention efforts, with frequent and robust sampling 
of the well- characterised cohort, allowing for detection 
of incipient pathophysiological, cognitive and functional 
changes that could inform therapeutic strategies to 
prevent and/or delay cognitive impairment and dementia. 
Dissemination of results will target the scientific 
community, research participants, volunteer community, 
public, industry, regulatory authorities and policymakers. 
On study completion, and following a predetermined 
embargo period, CPSS data are planned to be made 
Strengths and limitations of this study
 ► Prospectively designed, high- powered longitudinal 
cohort of cognitively healthy (at baseline) elders 
across the Alzheimer’s pathological continuum 
followed up at high throughput using biological, 
psychosocial, cognitive, behavioural and lifestyle 
measures.
 ► Study adopts a unique cognition- based classifica-
tion method for designating risk of mild cognitive 
impairment–Alzheimer’s disease development from 
baseline.
 ► Given the low amyloid positivity rate and the require-
ment of an equal number of CPSS participants above 
and below threshold, a high number of participants 
(78.6%) were excluded from the longitudinal CPSS 
study.
 ► The conduct of the study at only two sites does not 
fit the model of a typical, multisite international clin-
ical trial.









pen: first published as 10.1136/bm




2 Udeh- Momoh CT, et al. BMJ Open 2021;11:e043114. doi:10.1136/bmjopen-2020-043114
Open access 
accessible for analysis to facilitate further research into the determinants 
of AD pathology, onset of symptomatology and progression.
Trial registration number The CHARIOT:PRO SubStudy is registered with  
clinicaltrials. gov (NCT02114372). Notices of protocol modifications will be 
made available through this trial registry.
INTRODUCTION
Background and rationale
The last few decades have witnessed unparalleled 
growth in aged populations. Hence, the global inci-
dence and prevalence of Alzheimer’s disease (AD), the 
most common form of late- onset dementia, continue to 
increase exponentially, with numbers expected to exceed 
150 million global cases by 2050.1 The paucity of any 
viable therapy for dementia prevention and/or disease 
modification necessitates a rethink of the conventional 
approach towards preventative research. Indeed, the AD 
field will benefit from concerted efforts for preventative 
strategies combining biomarker discovery studies with 
detailed validation of clinical characteristics as well as 
longitudinal explorations of associated pathologies and 
symptoms.
The asymptomatic stage of AD is characterised by 
biomarker evidence of amyloid-β (Aβ) deposition, as 
measured by either low cerebrospinal fluid (CSF) Aβ42 
peptide concentrations or elevated tracer uptake on Aβ 
positron emission tomography (PET) scans.2 Multiple 
studies have now reported that higher Aβ burden in 
cognitively normal (CN) individuals is associated with 
measurably poorer performance in neuropsychological 
tests.3 The accumulating longitudinal data also strongly 
suggest that evidence of abnormal levels of Aβ deposition 
in CN individuals increases the risk for cognitive decline 
and progression to mild cognitive impairment (MCI) and 
AD dementia.3 The current consensus among members 
of the Alzheimer’s scientific community is that these CN 
individuals with detectable pathogenic Aβ represent an 
early stage on the AD continuum.2 4 5 Indeed, a meta- 
analysis of 55 studies suggested that approximately 20% 
to 35% of study participants aged over 60 years without 
dementia symptoms are likely to have above- threshold 
pathogenic Aβ pathology detected by PET,6 with numbers 
increasing to 90% by age 85.7
Rate of cognitive decline in CN individuals with or 
without evidence of abnormal Aβ deposition can be 
measured using sensitive cognitive composite instru-
ments. These measures focus on the cognitive domains 
affected earliest in AD, namely episodic memory and 
executive function, with decline noted as early as 7–10 
years prior to the diagnosis of MCI or AD dementia.8–10 
Yet, gaps remain in our understanding of the exact 
predictors of AD pathological onset, accumulation and 
resultant development of clinical symptoms. There is a 
need to identify individuals at varying levels of risk for 
AD, prior to development of AD dementia. Such informa-
tion would be useful to improve our understanding of the 
natural history of AD progression and identify opportuni-
ties for intervention.
The CHARIOT:PRO programme seeks to address 
such gaps via detailed explorations of the determinants 
of AD- related biological, clinical and cognitive changes. 
The previously reported main study of 987 participants 
at ICL, conducted from 2013 to 2016 (following early 
termination by the study sponsor)11 was further adapted 
into a large prospective observational trial—The 
CHARIOT: PRO SubStudy (CPSS) aimed at enhancing 
the scientific robustness of the main study objectives 
with the addition of imaging and other AD- related 
assessment tools.
Here, we describe the protocol (from Amendment 
version 15, dated 15 Aug 2018) of this biomarker 
enriched CPSS featuring neuropsychological, functional, 
lifestyle, imaging and other biomarker assessments and 
the schedule for their collection. We provide an outline 
of the study design and a summary of the recruitment and 
screening process leading to the fully enrolled cohort of 
519 cognitively unimpaired adults.
Objectives of the CPSS
CPSS is a prospective dual- centre, UK cohort study that at 
its core aims to characterise deeply the clinicobiological 
attributes of the non- symptomatic AD stage in individuals 
at differing levels of risk for development of MCI and AD 
dementia, based on cognitive test scores at screening. 
CPSS participants thus could form a readiness cohort to 
be recruited onto future AD dementia prevention trials.
Specifically, using data from participants with evidence 
of detectable Aβ pathology versus those with below- 
threshold levels, the study will:
 ► Investigate the longitudinal change of the global 
and composite measures of the newly- developed 
Global Preclinical Alzheimer’s Cognitive Composite 
(G- PACC) in comparison to the Repeatable Battery 
for the Assessment of Neuropsychological Status 
(RBANS)12 and other study neuropsychological 
assessments, as well as psychometrically evaluate the 
test batteries.
 ► Determine precise baseline predictors of longitudinal 
AD- related cognitive and functional decline, and clin-
ical progression to improve future screening of partic-
ipants most likely to develop MCI- AD/AD dementia.
METHODS
Population
The CPSS participants are adults aged 60–85 years old 
(inclusive), residing in Greater London, South West 
England, Edinburgh and surrounding districts. Those 
included had documented evidence of Aβ pathology 
(Aβ positives: above- threshold brain Aβ deposition on 
PET or below- threshold CSF Aβ42 concentration), or 
evidence of below- threshold Aβ pathology (Aβ negatives: 
below- threshold brain Aβ deposition on PET or above- 
threshold CSF Aβ42 concentration), and a baseline global 
Clinical Dementia Rating (CDR) score=0. CPSS partici-
pants were classified at screening as high, medium- amnestic 
or non- amnestic, or low risk for developing MCI due to 
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AD (MCI- AD), based on cognitive test performance as 
described previously.11
Study design
The CPSS is a UK prospective observational study taking 
place across two sites (ICL and EDI). The study is planned 
to follow approximately 250 CN participants who are Aβ 
positive and approximately 250 Aβ negative CN control 
participants for up to three and a half years. Evidence 
of Aβ pathology was assessed via CSF Aβ42 except where 
lumbar puncture (LP) was medically contraindicated 
or refused by participants, in which case Aβ PET was 
permitted as an alternative method of determination of 
Aβ status. CSF samples were tested with the Meso Scale 
Discovery (MSD) triplex (Aβ38/40/42). A binary classifi-
cation for Aβ load was applied using a cut- off value for 
CSF Aβ42 ≤ 600 ng/L. The cut- off for brain Aβ PET via 
standardised uptake value ratio (SUVR) was based on 
three independent F18- radiolabeled amyloid tracers—
florbetapir, flutemetamol and florbetaben. A specific 
SUVR threshold (ie, a cut- point) was used for each of the 
three radiotracers (Amyvid: 1.14 with whole- cerebellum 
as a reference region, Neuraceq: 1.20 with cerebellar 
grey matter, Vizamyl: 1.23 with whole cerebellum). 
Scans were reported as amyloid positive if the composite 
cortical SUVR value was above the defined tracer- specific 
threshold, and negative if less than or equal to the 
threshold value.
All study investigators, sponsor team and participants 
are blinded as to Aβ status information, with the exception 
of an unblinded team member for verification of imaging 
and CSF Aβ information. Blinding was put in place to 
avoid bias for conducting, monitoring and interpreting 
results from the clinical assessments (except for research 
analysis purposes). The same double blind is maintained 
for apolipoprotein E (APOE) genotype, in view of allele- 
specific positive correlation with Aβ load.13–15 Aβ status 
and APOE genotype results were not disclosed to partici-
pants as the clinical value (ie, diagnostic or predictive) of 
such a disclosure in a CN population is still unestablished. 
If clinical value is established from this or other studies, 
then amyloid and APOE genotype will be disclosed to 
participants, at the end of the study.
Numbers of Aβ negative participants who passed 
screening assessments were deliberately controlled to 
ensure equivalency with number of eligible Aβ positive 
participants. There was no deliberate effort to balance 
the groups by age or gender.
Study schedule
Participant recruitment
At the ICL site, participants were recruited primarily 
from the CHARIOT Register, a well- established dementia 
prevention and prediction register of older adults without 
dementia who have provided consent to be contacted 
for relevant ageing research.16 17 Some participants tran-
sitioned directly to CPSS from the main study, though 
most of these individuals had previously been recruited 
also from the CHARIOT Register. Additional methods 
of recruitment at the site, with very limited numbers 
of enrolled participants, included self- referrals and 
response from media advertisements. At the Edinburgh 
site, participants were recruited via SHARE (https://www. 
registerforshare. org), Join Dementia Research (JDR, 
https://www. joindementiaresearch. nihr. ac. uk/) and 
the Scottish Primary Care Research Network (SPCRN 
http://www. nhsresearchscotland. org. uk/ research- areas/ 
primary- care/ about- the- network) (see figure 1 for the 
participant recruitment pathway). Recruitment efforts 
resulted in 1914 individuals screened at ICL to enrol 409 
participants, and 537 screened at Edinburgh to enrol 
110. Screened participants were not selected based on 
race/ethnicity or gender, resulting in a predominance 
of participants of European ancestry (>95%) and a slight 
majority of women.
Selection of study participants: summary of eligibility criteria
The major exclusion criteria for CPSS include known 
familial autosomal dominant AD, diagnosis of AD 
dementia, MCI, or any other degenerative brain 
disorder that is associated with dementia at screening. 
Evidence of brain disease or other conditions leading 
to dementia, other than AD- related structural pathol-
ogies were assessed centrally by blinded neuroradiolo-
gists via MRI during screening. Additionally, use of AD 
pharmacological therapies, and evidence of psychiatric/
cognitive disorders/other abnormalities such as low 
vitamin B12 (specifically those with abnormal homocys-
teine and methylmalonic acid), and linked to cognitive 
deficits are exclusionary. Further, history of first- degree 
family member with diagnosed clinical AD was required 
for participants aged 60–65 years. This measure was put 
in place to enrich the cohort for cerebral Aβ positivity 
given typically lower prevalence in asymptomatic young 
elders, that is, below 70 years of age,18 thereby effectively 
Figure 1 The Cognitive Health in Ageing Register: 
Investigational, Observational and Trial Studies in Dementia 
Research (CHARIOT): Prospective Readiness cOhort (PRO) 
Substudy Recruitment Pathway. aJoin Dementia Research. 
bScottish Primary Care Research Network. cFormerly Centre 
for Dementia Prevention. dCHARIOT:PRO Main Study. 
eFormerly Neuroepidemiology and Ageing (NEA) Research 
Unit.
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minimising screen failure rates. Following participants’ 
consent, self- reported medical and medication history 
was confirmed from full history provided by participants’ 
general practitioner (GP). On receipt of any medical 
information, current medical conditions and medical 
history was updated on source documents and subse-
quently on electronic data, including medication, past 
and planned procedures. Medical summaries from GPs 
were used to ascertain self- reported histories.
During screening, participants whose cognitive perfor-
mance on any RBANS Index fell more than 1.5 SD below 
the (age and education adjusted) population mean 
(based on normative sample from19) were referred to 
an adjudication panel. This panel, comprising neurolo-
gists, psychiatrists and neuropsychologists, considered 
whether the low performance was likely to be attributable 
to undiagnosed cognitive impairment and, if so, excluded 
the participant from the study. These participants were 
contacted directly by the study team to inform them of 
their exclusion. At that time, where any concerns were 
noted regarding their performance, the option to notify 
their GP with information about the study and their 
exclusion was offered.
Screening schedule
The screening was usually completed in four separate 
visits within a 90- day window. On certain occasions, this 
timeline was extended up to 180 days to allow for treat-
ment of transient conditions, laboratory retesting and 
scheduling of other screening assessments. This allowed 
time for results to be received and evaluated against study 
eligibility criteria. Any clinically significant findings were 
passed on for follow- up to the participant’s GP. Partici-
pants who were determined to have an active unstable 
illness, as defined by the inclusion/exclusion criteria, 
were excluded. Screening involved collection of demo-
graphic data which included age, ethnicity, education 
and occupational status. During screening, potential 
participants completed cognitive tests, the G- PACC and 
RBANS, and CDR including the study partner interview. 
A clinical evaluation (pulse, blood pressure, weight, head, 
waist and hip circumference, temperature (tympanic), 
physical and neurological examination) and clinical lab 
assessments were carried out to determine general health 
status. Participants not excluded at this stage then under-
went a brain MRI. If MRI did not reveal exclusionary 
abnormalities (see box 1), it was followed by an Aβ assess-
ment based on CSF analysis or brain PET scan. After 
the Aβ determination, baseline assessments were under-
taken at two consecutive visits where the RBANS (form 
A), G- PACC (form A) as well as the Neuropsychological 
Assessment Battery (NAB) Memory and Executive Func-
tion modules (form 1) and the National Adult Reading 
Test (NART) were administered alongside self- reported 
study questionnaires. Biosamples were further collected 
for biomarker assessments (see figure 2 for schematic 
depiction of screening and baseline assessments).
Postscreening schedule
Following the baseline assessment, CPSS participants 
were randomised in a balanced 1:1:1 ratio, stratified by 
Aβ status and level of performance on the screening 
RBANS, to one of three supplemental neuropsycholog-
ical tests namely: CogState Brief Battery,20 Cognitive Drug 
Research Assessment System, and either Delis- Kaplan 
Executive Function System (DKEFS, 21, ICL only) or 
COGNITO (22, EDI only). Participants who enrolled in 
the Substudy from the Main Study retained their previous 
Main Study- assigned randomised group. Participants are 
expected to attend study visits every quarter and will be 
followed up for a period of up to 3.5 years. Due to the 
COVID-19 restrictions that were implemented in March 
2020 in the UK, the CPSS was transitioned to virtual 
visits to allow continued longitudinal assessments. For 
further details on our strategy for operationalising this 
activity, see Ref 21. As part of the general visits, we collect 
detailed information on all medical, especially COVID-
19- related incidents including more recently information 
on COVID-19 vaccinations. These data are designated 
COVID-19- related within our database for easy identifica-
tion of such cases.
Study outcomes and assessments
Primary neurocognitive outcomes
The primary outcomes of the CPSS are performance in 
two neurocognitive measures, the novel G- PACC and the 
RBANS.
The G- PACC: is a retrospectively and theoretically 
derived and validated measure, weighted towards 
episodic memory but including a timed executive func-
tion test and a global cognitive screening test.22 For this 
study, the four PACC components include: the Free 
Box 1 Cognitive Health in Ageing Register: 
Investigational, Observational and Trial Studies in 
Dementia Research: Prospective Readiness cOhort study 
exclusionary findings post screening MRI
Oedema including amyloid- related imaging abnormalities (ARIA- E)
Hydrocephalus
>25% age related white matter disease
Frontal or temporal atrophy not typical of AD
History or evidence of a single prior haemorrhage >1 cm3
Multiple lacunar infarcts (two or more) or




Space- occupying lesions (eg, abscess or brain tumours such as me-
ningioma >1 cm)
MRI features atypical of AD dementia.
*Evidence of brain oedema (eg, ARIA- E, vasogenic oedema, hemosiderin 
deposits (HD)≥10 mm in size or HD <10 mm in size but >10 in number) will 
be reviewed by the Sponsor’s Medical Monitor to address plans for clinical 
evaluation and follow- up as well as for potential inclusion/exclusion in the 
study.
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and Cued Selective Reminding Test—Immediate Recall 
(FCSRT- IR),23 the Delayed Paragraph Recall score on a 
single administration of the Logical Memory story from 
the WMS—Revised,24 the WAIS- IV Coding subtest24 and 
the MMSE.25 Each component score is transformed 
into z- scores. These z- scores are summed to form the 
composite. The battery takes about 25 min to administer. 
Alongside screening and baseline time points, alternating 
forms of the G- PACC are administered at the following 
time points: months 6, 12, 18, 24, 30, 36, and 42.
The RBANS: is a 25 min composite battery with 12 
subtests that measure 5 cognitive domain indices: Atten-
tion, composed of Digit Span and Coding, Language, 
with Picture Naming and Semantic Fluency subtests, 
Visuospatial Construction including Figure Copy 
and Line Orientation subtests, Immediate Memory 
comprising List Learning and Story Memory subtests, 
and Delayed Memory composed of List Recall, List 
Recognition, Story Recall and Figure Recall subtests. 
The sum of these 5 Index scores is converted to a 
Total Scale value via a mapping table. The Total Scale 
is a norm- based t- score based on a distribution with 
a mean of 100 and SD of 15. The RBANS is adminis-
tered face- to- face, has 3 alternate forms, is available in 
over 30 languages, and has been used in multinational 
clinical trials including AD trials. Alternating forms 
of the RBANS are also administered at the following 
timepoints: months 3, 9, 15, 21, 27, 33, and 39. During 
screening, participants’ RBANS scores were used to 
delineate risk (low, medium, high) for developing MCI- 
AD, as described in the Main study.11
Secondary cognitive outcomes and functional outcomes 
are described in table 1. More detailed description of 
these measures are provided in the CHARIOT PRO Main 
Study Protocol.11
Neuroimaging outcomes
Safety and volumetric scans (3DT1, FLAIR, T2*, PD/T2, T1 and DWI)
All potential CPSS participants underwent brain MRI at 
screening to assess eligibility, based on a central radiolo-
gist’s interpretation of the MRI scan under the supervision 
of Bioclinica. Borderline findings were reviewed by the 
Medical Monitor prior to determining participant eligi-
bility. Image acquisition was performed at multiple sites 
based on a standardised MRI protocol. General Electric 
Signa HDxt 1.5T and Siemens TrioTim, Verio, Skyra and 
Prisma 3T scanners were used to acquire a volumetric 3D 
T1 weighted series in a sagittal plane, using 1.2 mm thick 
slices and a 192×192 acquisition matrix over a square FOV 
of 240 mm. Contrast parameters were field strength and 
manufacturer dependent (Siemens MP- RAGE and GE 
IR- Prep Fast SPGR). The standardised MRI protocol also 
included 2D axial FLAIR, T2* gradient echo, dual- echo 
proton- density and T2- weighted turbo/fast spin echo, 
T1- weighted turbo/fast spin echo and diffusion- weighted 
imaging. Proper implementation of the MRI protocol 
on each participating scanner was verified prior to first 
subject scan by use of American College of Radiology 
(ACR) phantom scans.
Exploratory scans (task-free BOLD functional MRI (tf-fMRI) and 
high-resolution coronal T2 sequences)
At the ICL site, the first 800 subjects who were eligible 
for MRI underwent a dual- echo GRE field map and task- 
free functional MRI time series. For the remainder of the 
subjects, a high- resolution two- dimensional (2D) coronal 
T2- weighted sequence was acquired, in order to visualise 
hippocampal subfields.
Figure 2 Screening and baseline assessment schedule. CDR, Clinical Dementia Rating; CSF, cerebrospinal fluid; PACC, 
Preclinical Alzheimer Cognitive Composite; PET, positron emission tomography; RBANS, Repeatable Battery for the 
Assessment of Neuropsychological Status; CFI, Cognitive Function Index; ADCS- ADL- PI, ADCS- Activities of Daily Living—
Prevention Instrument; NAB, Neuropsychological Assessment Battery; NART, National Adult Reading Test; GDS, Geriatric 
Depression Scale; STAI, State Trait Anxiety Inventory.
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Table 1 Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research 
(CHARIOT): Prospective Readiness cOhort (PRO) study Cognitive and Functional outcomes
Cognitive outcome Description Assessment schedule
Secondary outcomes
  National Adult Reading Test 
(NART)29
The NART is a word reading and pronunciation task comprising 50 English 
words with irregular grapheme- phoneme and stress rules. It is used to provide 
an estimate of premorbid intellectual functioning. Average administration time: 
10 min.
BL
  Neuropsychological 
Assessment Battery (NAB) 
Executive Function module 
(PAR)30
The executive function module comprises subtasks that examine planning, 
impulse control and psychomotor speed (through pen and paper mazes trials 
of increasing difficulty); judgement and decisional capacity (through questions 
pertaining to home safety, health and medical issues); concept formation, 
cognitive flexibility and response set (through a classification and categorisation 
task) and fluency and generativity (through a word fluency task). Average 
administration time: 30 min.
M12, M24, M36
  Neuropsychological 
Assessment Battery (NAB)—
Memory module (PAR)
The memory module comprises explicit learning, free recall, delayed recall and/
or delayed recognition subtasks across verbal (list learning; story learning; 
medication instructions and name and address) and visual (shape learning) 
information. Average administration time: 45 min.
M12, M24, M36
  NEUROTRACK (Neurotrack 
Technologies)31
Neurotrack is a declarative memory test based on digital eye tracking, 
administered on an IPAD. The task is a recognition memory test, relying on an 
individual’s innate preference for novelty. In a familiarisation phase, participants 
are presented with two identical images, side by side on the computer screen. 
This is followed by a test phase, in which a familiar image presented during the 
familiarisation phase and a novel image are shown together. The ratio of time an 
individual gazes at the novel stimulus relative to the total viewing time constitutes 
a novelty preference score, with higher scores indicating superior declarative 
memory function and lower scores indicating impaired function. Average 
administration time: 10 min.
M3, M9, M15, M21, M27, 
M33, M39
Randomised tasks
  Cognitive Drug Research 
Assessment System (CDRAS) 
(Bracket; United BioSource 
Corporation)32
The CDRAS measures three domains of cognition: Attention (simple and choice 
reaction time, digit vigilance); Working memory (articulatory and spatial working 
memory); Episodic secondary memory (word recall, word recognition and picture 
recognition). Average administration time: 20 min.
M3, M9, M15, M21, M27, 
M33, M39
  Cogstate (Cogstate)20 CogState consists of 4 tasks involving the presentation of playing cards. These 
tasks measure the functions of attention, processing speed, visual learning, and 
working memory using standard psychometric paradigms (ie, simple and choice 
reaction time, n- back and pattern separation learning). For the first assessment 
visit, M3, the task is administrated twice within one session to control for task 
familiarity and practice effects. Average administration time: 15 min.
M3, M9, M15, M21, M27, 
M33, M39
  Delis- Kaplan Executive 
Function System (Pearson)33
  ICL Site Only
The DKEFS is a paper and pencil measure of verbal and nonverbal executive 
functions and comprises nine subtests. For this study, the Trail Making Test 
(visual attention and task switching) and Verbal Fluency (fluency and generativity) 
subtests are used. Total average administration time to complete these two 
subtests:15 min.
M3, M9, M15, M21, M27, 
M33, M39
  Cognito34
  EDI Site Only
COGNITO is a computerised task which assesses reaction time, primary and 
working memory (an articulation subtest further permitting identification of 
problems related to the articulatory loop), visuospatial and verbal secondary 
memory (with free, cued and multiple choice paradigms), implicit learning 
(priming), language skills (word and syntax comprehension, naming, verbal 
fluency), functional and semantic categorization of visual data (visual reasoning 
and form perception), focused and divided attention (visual and auditory 
modalities), and crystallised intelligence (vocabulary). Responses are made via 
a tactile screen which permits the recording of response latency (deducting 
reaction time provides an estimation of information processing time). Qualitative 
aspects of performance (perseveration, intrusions, visual field neglect) are also 
recorded. Administration time varies between 45 to 60 min, depending on level of 
impairment.
M3, M9, M15, M21, M27, 
M33, M39
Continued
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Amyloid-β positron emission tomography
At final stage of screening, evidence of Aβ pathology in 
potential CPSS participants was assessed by a brain PET 
scan. All images derived were evaluated centrally at Biocl-
inica for Aβ status assessment. The assessments were 
performed by neuroradiologists trained in the assessment 
of Aβ PET scans using F18- radiolabeled amyloid tracers 
(Amyvid, Vizamyl and Neuraceq) for amyloid status 
according to the reading process developed by radio-
tracer vendors. The PET scan was evaluated at baseline to 
determine each patient’s Aβ status as positive or negative 
and therefore inclusion or exclusion into the trial. PET 
exams were acquired using a uniform scanning protocol 
that minimises and accounts for between- site differ-
ences in PET systems, as characterised with a Hoffman 
phantom exam. All exams were acquired in 3D mode 
and employed correction for attenuation, scatter and 
random coincidence. Semiquantitative SUVR assessment 
was performed prior to the visual read. SUVR calculations 
leveraged a FreeSurfer- based native- space MRI segmenta-
tion method. The Aβ status assessment was a hybrid visual 
and quantitative approach (see figure 3). A visual review 
was performed by a single reader, followed by positivity 
assignment based on SUVR cutpoint. In case of discrep-
ancies between visual and SUVR results, a second reader 
was asked to participate in a final decision on amyloid 
status, as part of a consensus review. The second reader 
was given both the initial visual read and the SUVR 
measurement and convened with the first reader to arrive 
at a consensus assessment.
Fluid biomarkers
Blood, saliva and urine samples for clinical assessments and future 
biomarker discovery studies
At ICL and EDI, blood and urine samples were collected at 
screening to assess general health status. These included: 
haematology and differential panel, lipid panel, chemistry 
panel, electrolyte panel, coagulation group, C reactive 
protein, TSH, folate, vitamin B12 and urine macropanel 
(with urine microscopy if abnormal macro panel).
At ICL, serum, plasma, buffy coat, whole blood, urine 
and saliva samples are processed and stored at baseline 
and annually thereafter for future biomarker explo-
ration. Samples for biobanking are collected between 
9:00 and 11.30 and following an overnight fast; and 
are stored at the ICL purpose built −80°C biobank 
for future analyses. All samples are processed within 
2 hours of collection, as per guidelines on biomarker 
preprocessing.26 Planned analyses include untargeted 
metabolite and proteome profiling, to generate novel 
targets for future hypothesis testing and biomarker 
discovery studies.
CSF biomarkers
For those participants not receiving Aβ PET, CSF 
samples were collected during screening and analyses for 
AD- related markers including beta- amyloid, total tau and 
phosphorylated tau. The Aβ data were used for determi-
nation of enrolment eligibility, and in addition to the tau 
data, will be useful for disease modelling and staging of 
preclinical AD per NIA- AA criteria.2 At ICL, additional 
aliquots of CSF samples are stored in the −80°C biobank 
for future analyses, which may include the exploration of 
putative biomarkers of AD pathophysiology as they arise 
in the literature.
Functional outcomes Description Assessment schedule
Clinical Dementia Rating 
Scale35
The CDR is used as a clinical staging instrument and is administered to both 
participant and study partner, using a semistructured format. It assesses six 
domains: memory; orientation; judgement and problem solving; involvement in 
community affairs; home and hobbies; and personal care. Average administration 
time: 15–20 min with the study partner and 10–15 min with the participant, 
depending on the severity of cognitive impairment.
M12, M24, M36
Cognitive Function Index36 The CFI is a modified version of the Mail- in Cognitive Function Screening 
Instrument (MCFSI, Walsh et al, 2006) a self- reported and informant- reported 
subjective outcome measure regarding activities of daily living. It includes 14 
questions that assess participants’ perceived ability to perform high level tasks in 
daily life and their sense of overall cognitive functional ability, indicating whether 
or not there has been a change in performance (yes/no/maybe) compared with 
1 year ago. Study participants and their study partners independently rate the 
participant’s level of ability. Average administration time: 10 min.
M12, M24, M36
Alzheimer’s disease 
Cooperative Study ADL 
prevention instrument (ADCS- 
ADL- PI)37
The ADCS- ADL- PI includes 15 subjectively rated questions related to activities 
of daily living and 5 questions related to physical functioning. Study participants 
and their study partners independently rate the study participant’s level of 
ability. Partners are additionally asked to evaluate whether activities were 
completed less often, required more time to complete, and if errors were made 
performing the task. Physical functioning items are rated as yes or no. Average 
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Genetic outcomes
Whole blood is collected in EDTA tubes for extraction of 
genomic DNA (gDNA) using standard methods. gDNA 
were thus isolated via commercially available kit following 
manufacturer instructions (QIAgen QIAsymphony DSP 
DNA Mini Kits or Promega Maxwell RSC Whole Blood 
DNA Kit). Both kits facilitate automated magnetic bead- 
based extractions that successfully extract DNA from 
human whole blood samples with good quantitation and 
purity assessments. The QPS validated pyrosequencing 
genotyping assays for APOE codon 112T>C and codon 
158C>T polymorphic variants were used to genotype 
participant’s gDNA samples and identify APOE ɛ4 Carriers 
and APOE ɛ4 Non- Carriers status. By interrogating these 
two polymorphic variants, we identified the three APOE 
alleles: APOE ɛ2(TGC 112, TGC 158), APOE ɛ3 (TGC 
112, CGC 158), and APOE ɛ4 (CGC 112, CGC 158). APOE 
genotype status has been determined for the enrolled 
cohort. A genome- wide- analysis study is underway and 
data expected to be available during the study. At ICL, 
whole blood is also collected in a PAXgene Blood RNA 
tube containing reagent for stabilisation of intracellular 
RNA, and stored −80°C. These samples will be used for 
future genetic analyses.
Medical history and clinical examinations (physical and 
neurological examination)
A thorough medical history was obtained including an 
evaluation of all body systems (ear, nose, throat (ENT), 
ophthalmic, musculoskeletal, gastrointestinal, urinary, 
respiratory, renal, cardiovascular, dermatological) with an 
emphasis on relevant medical history (eg, neurological, 
psychiatric, substance abuse, endocrine and metabolic). 
Safety and compatibility for neuroimaging were further 
ensured prior to the procedure.
Clinical examination included general physical exam-
ination and a separate comprehensive neurological 
physical examination. the general physical examination 
assessment included: general appearance, dermatological 
(including mucous membranes), ENT, cardiovascular, 
respiratory, abdomen, lymph nodes, musculoskeletal and 
any other findings. At neurological examination, mental 
status, cranial nerves, motor (strength), tone, involun-
tary movements, coordination (finger- nose, gait, postural 
reflexes and heel to shin), sensation (proprioception, 
cold, light touch), deep tendon reflexes, plantar reflexes 
and presence of other neurological signs (eg, tremor) 
were assessed.
Safety reporting
During the whole course of the study, new medical condi-
tions and changes in medication were assessed at every 
site visit. All adverse events (serious and non- serious) 
were documented and reported according to the same 
protocol procedures applied in the main CHARIOT:PRO 
Main Study.11 Briefly, serious and non- serious events that 
occur from inception of participation all through to 
completion of last study- related procedure are captured 
and recorded for all participants. Events are judged as 
serious if fatal, immediately life- threatening; require 
hospitalisation or prolonging of existing hospitalisation; 
permanently (or significantly) disabling; a congenital 
Figure 3 Positron emission tomography (PET) amyloid-β (Aβ) status reading workflow. SUVR, Standardised Uptake Value 
Ratio; Q, quantification of SUVR; FS, parcellation of cerebral structures based on Freesurfer imaging pipeline; QC, quality 
control assessment; VIS, result of visual assessment of amyloid PET; Aβ+, assessed as Aβ positive based on visual and/or 
quantitative (SUVR) analysis of amyloid PET.
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anomaly or birth defect (in an offspring); or medically 
significant. Further data recorded for each suspected 
adverse event included the description (signs and symp-
toms or diagnosis), seriousness criteria, severity rating, 
duration (onset and resolution date), actions taken and 
outcome.
Study participant and public involvement
The ICL (via CHARIOT register) and EDI team have 
established Research volunteer panels consisting of lay 
members who met on an ad- hoc basis to support study 
development during the planning stage. These panels 
provided feedback on study design, procedures and 
dissemination for lay audiences. A newsletter is provided 
to study participants with updates regarding recruit-
ment, study milestones and any important changes to 
the protocol. Participants were not directly involved in 
recruitment activities for the study.
CPSS participants further provide feedback on the 
experience of research participation at the different study 
visits, to ensure that their perspectives are represented in 
decision- making about the future of the project and to 
advise on planned study activities, including dissemina-
tion plans. Annual participant seminars are conducted 
for dissemination of study results and discussion of future 
plans. A newsletter is provided to study participants quar-
terly for study updates, as well as future plans. Participant 
input and feedback on volunteer experiences is typically 
encouraged for inclusion in the newsletter.
Ethical and regulatory considerations
To ensure the quality and integrity of research, CPSS is 
conducted in accordance with GCP Guidelines, GPPs 
issued by ISPE, applicable national guidelines, and to the 
Declaration of Helsinki 2013, as modified by the 52nd 
World Medical Assembly (WMA), Edinburgh, Scotland, 
2000, and clarified by the WMA General Assembly, Wash-
ington 2002 and Tokyo 2004. The study has received 
approval from the National Research Ethics Service 
(NRES) Committee London Central (reference 15/
LO/0711 (IRAS 140764)), as well as independent ethics 
review by committees from the local sites.
Informed consent
Formal informed consent is taken using an informed 
consent form (ICF) from both participant and study part-
ners before participation in the study. Given the possibility 
that participants might lose mental capacity during the 
study; it was recommended at the outset of participation 
that the participant identified a Legally Authorised Repre-
sentative (LAR). A LAR may include the spouse, a person 
specifically appointed to take care of the legal interests 
of the participant, an individual with guardianship, and 
a healthcare proxy, who provides consenting for research 
studies which is within the legal scope of the proxy’s dele-
gated responsibilities (according to local applicable laws). 
The LAR must have the cognitive and mental capacities 
(as determined by the site investigator) enabling him/
her to understand the procedures, risks and benefits 
involved with the study. The consent was given, and the 
form signed, at the initial visit or at follow- up visits at the 
study sites, based on the choice of the participant, and, 
where necessitated, on the choice of the LAR.
Duty of care
As part of the duty of care during the study, all clinically 
relevant information is shared with study participants 
where relevant and, with participant’s consent, commu-
nicated to the GP for medical follow- up. The clinically 
relevant findings shared included systemic hypertension 
and significant changes in cognitive assessments where 
the investigator felt they were relevant.
Confidentiality
Participant confidentiality is strictly maintained. Each 
participant is assigned a unique participant identifier on 
study enrolment, which is used for all subsequent data 
analysis and reporting. Participants’ National Health 
Service (NHS) numbers are collected and stored in 
keeping with industry standards for encryption/data 
protection, allowing for subsequent data collection from 
electronic health records in primary or secondary care 
within NHS. This data collection only occurs following 
NRES approval. All parties ensure that participant 
personal data is not included on any study forms, reports, 
publications, or in any other disclosures, except where 
required by law. The Investigators in compliance with 
Federal regulations, other applicable laws and Inter-
national Conference on Harmonization (ICH) GCP 
Guidelines keep documents that are not for submission 
to the sponsor and/or its designee (eg, signed ICFs and 
Participant Information Sheets) in strict confidence. In 
accordance with regulations in the UK, participants are 
informed about data handling procedures.
Data management, analysis, and dissemination plans
Data management
The CPSS is conducted in accordance with Good Clin-
ical Practice (GCP) Guidelines as such data are recorded 
and stored in a way that could be verified and reported 
in an accurate manner. All essential documents are filed 
in the trial master file/investigator site file. Source docu-
ments are kept in both paper and electronic formats. The 
main Electronic Data Capture system used in the current 
study is Medidata Rave. Both paper and electronic data 
are subject to daily and monthly internal audits based on 
standard operating procedures (SOPs). In addition, the 
investigator site files, paper source documentation and 
electronic source data are routinely monitored to main-
tain data accuracy collection to the highest degree.
Statistical analysis
Assuming the 3.5 year change from baseline in the 
G- PACC score has a SD of 2.4 for the Aβ positive partic-
ipants,27 a sample size of n=250 with a 3.5- year dropout 
rate of 31% (ie, 10%/year) ensures the 95% CI for the 
3.5- year mean change in G- PACC score in Aβ positive 
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participants to be no wider than 0.72, assuming that 
the sample mean follows a Gaussian distribution. Anal-
ysis of change in G- PACC and RBANS over time will be 
performed with mixed models for repeated measures 
(MMRM) which assumes that missing data due to 
dropout are missing- at- random (MAR). The robustness 
of the analysis with respect to deviations from the MAR 
assumption will be evaluated. Analyses of the accruing 
results may be performed periodically while the study is 
ongoing. Analyses will generally be descriptive, but infer-
ential analyses might be performed as needed. Potential 
unblinded interim analyses include:
1. Analyses for baseline characterisation of participants.
2. Analyses for determining longitudinal change in study 
endpoints once the last ongoing subject completes the 
month 12, month 24 and month 36 visits. These anal-
yses will include descriptive statistics (n, mean, SD) 
and/or proportions for the Aβ positive and negative 
groups, but the Aβ status of individual participants will 
remain blinded.
DISCUSSION
With the preclinical disease stages being increasingly 
recognised as the best timing for intervention, it is 
paramount that trial evaluations are sensitive enough 
to detect and track cognitive, functional and biological 
changes emerging in these stages while also possessing 
sufficient efficacy to detect therapeutic effects for drug 
trials. Furthermore, there is an urgency to identify robust 
and sensitive predictors of clinical progression in order to 
estimate individual risks for clinical AD and develop and 
apply therapeutic strategies prior to emergence of clini-
cally evident AD dementia. Although an ambitious project, 
some limitations of this work are worth mentioning. The 
amyloid positivity rate is low and due to a need for an equal 
number of participants in each group (amyloid positive; 
amyloid negative), a high number of participants (78.6%) 
were excluded from the longitudinal follow- up phase. As 
a mitigating measure, enrichment criteria were intro-
duced, with requirement of first- degree family history in 
volunteers aged 60–65 years old. The conduct of the study 
at only two sites is not typical of multisite international 
trials; on the other hand, this minimises several sources 
of variability that are independent of ageing and incip-
ient Alzheimer’s disease (eg, inter- rater variability and 
differences in psychometric equivalence among different 
translations). It could be argued that the cognitive battery 
set may not be sensitive in predicting AD in healthy older 
adults, since these mostly tax modalities associated with 
AD dementia diagnostic criteria. Nonetheless, the high 
frequency (quarterly) follow- up of participants will facil-
itate determination of those assessments most sensi-
tive for identifying the earliest signs and symptoms of 
AD- dementia and offers an opportunity to assess other 
performance parameters (eg, qualitative errors, lack of 
practice effect; speed- accuracy tradeoffs) that may indi-
cate changes in cognitive and/or cerebral integrity in the 
lead up to AD dementia.28 Similarly, other assessments of 
physical health pertinent to AD risk, such as gait, hearing, 
or dental health are not included in our study. However, 
we do collect extensive medical history information at 
baseline and follow- ups that includes clinical abnormali-
ties (eg, mobility issues; hearing impairment) that may be 
useful in our analyses.
The CPSS contributes towards this global agenda of 
AD- dementia prevention. The study features detailed and 
frequent clinical and cognitive assessments in a deeply 
phenotyped, presymptomatic cohort of older adults. 
An overall aim of the study is to prospectively compare 
changes in cognition, and other clinical measures, 
between individuals with presence of pathological levels of 
brain Aβ detected in PET scans or CSF and those without 
such evidence. CPSS also introduces a novel cognitive 
composite, the G- PACC, as a possible endpoint for future 
clinical trials. In this way, CPSS will expand on prior retro-
spective investigations of proposed cognitive composites,27 
by prospectively investigating the longitudinal change of 
the components of the G- PACC composite. The perfor-
mance of the G- PACC to detect effects will be compared 
against another cognitive composite and its subtests, the 
RBANS. The addition of the RBANS subtests, alongside 
other clinical data, will allow for the exploration of novel 
cognitive risk profiles for the progression of future AD. 
The baseline data will determine which measures are 
most sensitive for predicting longitudinal AD- related 
cognitive decline, informing future screening methods 
for clinical trials. The study includes both patient and 
proxy versions of functional interviews, such as the CFI 
and ADCS- ADL, to investigate longitudinal changes in 
everyday functioning in preclinical- AD individuals along-
side cognitive decline and clinical characteristics. Dietary 
patterns and other lifestyle variables will also be assessed 
to consider the impact of environmental exposures on 
AD development. Therefore, the CPSS will also allow for 
the exploration of environmental and lifestyle predictors 
of cognitive decline and impairment.
The uniqueness of this study lies in its breadth and 
frequency (every 3 months) of assessments, as well as 
the planned explorations and comparisons of proposed 
cognitive composites for AD detection and tracking. The 
prolonged and detailed follow- up data offers opportuni-
ties for precise disease modelling and the evaluation of 
several methodological controversies within clinical trial 
design, such as the influence of practice effects on cogni-
tive performance, in addition to mechanisms of reserve 
and resilience against cognitive senescence.
To date, CPSS has successfully completed its enrol-
ment of 519 participants across two UK research sites, 
from 2451 screened volunteers. Next steps in CPSS’s 
milestones include the exploration of the baseline data 
for initial comparative analyses between stratified partic-
ipant groups. The CPSS will continue as a multinational 
and multidisciplinary collaboration between industry, 
academia and the NHS to promote greater under-
standing of the aetiology of AD pathological attributes 
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and symptom development, and champion the search 
for effective preventative therapies. Future plans include 
study extension to at least 4.5 years, at the ICL site, with 
addition of Tau- PET and follow- up structural MRI, and 
extensive state- of- art fluid biomarker discovery explora-
tions at multiple timepoints.
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